ABSTRACT. Muscarinic cholinergic receptors were identified and partially characterized in crude membrane fractions of rat lung and trachea from day 17 of gestation to adulthood using (-)-[3 ...
Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, No. 23 (June 8, 2021), pp. 1-12 (12 pages) The construction and maturation of the postsynaptic apparatus are ...
Background. Stimulation of the vagus nerve in the so-called cholinergic antiinflammatory pathway (CAP) attenuates systemic inflammation, improving survival in animal sepsis models via α7 nicotinic ...
Formally known as KarXT, xanomeline-trospium chloride (Cobenfy) receives approval from the FDA for the treatment of schizophrenia in adults. The FDA approved xanomeline and trospium chloride (Cobenfy) ...
Xanomeline-trospium (KarXT) — a novel therapy that combines a muscarinic receptor agonist with an anticholinergic agent — led to statistically significant and clinically meaningful improvements in ...
Adjunctive use of xanomeline/trospium chloride (Cobenfy) offered no statistically significant benefit over placebo in adults with symptoms of schizophrenia inadequately controlled by an atypical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback